Despite numerous research and medical advances, Cancer remains the number one cause of death, and one in two people born today will be diagnosed with cancer at some point during their lifetime.

The uncontrolled growth of cancer cells is to a large extent determined by stimuli in their immediate environment. At Merrimack, we are focused on understanding the combinatorial activity of these stimuli and how to regulate them to stop cancer.

Merrimack has extensively modeled key signaling networks regulating the biology of solid tumors, including breast, ovarian and colon cancers. Based on this research, we have developed several novel approaches to attack and shut down the growth signals that drive the growth of tumors. We have developed a portfolio of therapeutic candidates based on our discoveries and are currently testing two novel therapeutic antibodies, MM-121, in Phase 1 development, and MM-111 which is expected to enter clinical development in the middle of 2009.

[ back to top ]